Ibogaine for Nicotine Addiction: What the Evidence Shows

Nicotine dependence (ICD-10 F17.2) is a pattern of compulsive nicotine use. It continues despite harm, and stopping brings withdrawal symptoms such as irritability, anxiety, trouble concentrating, increased appetite and strong cravings. The same dependence can form whether nicotine comes from cigarettes, e-cigarettes (vapes) or oral nicotine pouches such as Zyn, though the products deliver it at different speeds and in different patterns.

The products people use are shifting:

• In US adults, e-cigarette use rose from 4.5% in 2019 to 6.5% in 2023. Use was highest among young adults aged 21–24, at 15.5%, according to the CDC's National Center for Health Statistics.
• In the 2024 National Youth Tobacco Survey, 1.8% of middle and high school students (about 480,000) currently used nicotine pouches, including 2.4% of high school students. Pouches were the second most commonly used tobacco product among US youth, after e-cigarettes.

Many people who look up ibogaine for nicotine addiction have already tried to quit several times. That frustration is understandable. The rest of this page sets out what the evidence actually supports, which matters all the more because nicotine dependence already has treatments proven in randomized trials, while ibogaine carries serious cardiac risk.

Treatment for nicotine dependence has one of the larger evidence bases in addiction medicine. Options include:

• Nicotine replacement therapy (NRT): patches, gum, lozenges, inhalers and sprays. Using a long-acting form together with a short-acting one is common practice.
• Varenicline: a partial agonist at nicotinic receptors that reduces both craving and the reward from smoking.
• Cytisine (cytisinicline): a plant-derived partial agonist that works in a similar way. It is available in some countries and still investigational in others.
• Bupropion: an antidepressant that is also approved for smoking cessation.
• Behavioral support: counseling, quitlines and text-message or app programs, which add to the effect of medication.

What the trials show. A 2023 Cochrane review of randomized controlled trials found that both cytisine and varenicline help more people quit smoking than placebo or no medication. It also found high-certainty evidence that varenicline helps more people quit than a single form of NRT (risk ratio 1.25). The reviewers judged that people taking varenicline are probably somewhat more likely to have serious adverse events than people not taking it, though the evidence on specific harms was imprecise. They also noted that cytisine may lead to fewer reported serious adverse events than varenicline.

Vaping. Trials of treatments for e-cigarette dependence are newer. In a 2025 randomized clinical trial in JAMA, young people who vaped were given varenicline or placebo alongside behavioral support. Continuous abstinence in the last month of treatment was 51% with varenicline versus 14% with placebo, and 28% versus 7% at six-month follow-up.

Nicotine pouches. We found no published randomized trials testing cessation treatments specifically in people who use pouches. Clinicians generally adapt the approaches used for smoking and vaping.

None of these treatments works for everyone, and relapse is common. Still, each has been tested in controlled human trials with measured safety outcomes, which no form of ibogaine has had for nicotine dependence.

Ibogaine is an alkaloid from the root bark of the West African shrub Tabernanthe iboga. Scientific interest in it for nicotine comes from pharmacology and animal studies, not from clinical trials in people.

Mechanisms that have been proposed include:

• Nicotinic receptor blockade. Laboratory studies describe ibogaine and related compounds as noncompetitive antagonists at several nicotinic acetylcholine receptor subtypes, especially α3β4. These receptors are concentrated in the medial habenula–interpeduncular pathway, a circuit linked to nicotine aversion and withdrawal.
• Blunted dopamine response. In rats, ibogaine given about 19–22 hours before nicotine reduced the rise in dopamine in the nucleus accumbens that nicotine normally causes. This dopamine rise is thought to contribute to nicotine's rewarding effect.
• A long-acting metabolite. In the body, ibogaine is converted to noribogaine, which stays in circulation much longer and has its own effects on receptors and transporters. Researchers have suggested this could explain effects that outlast the acute experience.

Evidence level: these are mechanistic hypotheses supported by in vitro and rodent data. No one has shown that any of these mechanisms produces lasting nicotine abstinence in humans. Ibogaine also acts on many other targets, including cardiac ion channels, and that is the main source of its danger.

Animal studies (rats). The most direct evidence comes from a small set of rat experiments, mostly from the 1990s:

• Benwell and colleagues (1996) found that ibogaine pretreatment dampened nicotine-induced dopamine overflow in rats. They also observed long-lasting anxiety-like behavior in the animals and concluded that this needed further investigation before ibogaine could be recommended for smokers.
• A 1998 review by Glick and Maisonneuve summarized rat findings in which ibogaine reduced nicotine's dopamine effects and nicotine preference. Other reviews of this work note that the effects on nicotine were shorter-lived than those seen with some other drugs.

Human evidence. This is where the gap is largest:

• No randomized controlled trial, and no prospective observational study, has tested ibogaine for smoking, vaping or nicotine pouch dependence.
• A 2023 systematic review of ibogaine and noribogaine for substance use disorders found that tobacco appears in the human literature mainly as a substance participants also used. Nicotine abstinence was not measured as an outcome.
• The only accounts we found that focus on smoking are anecdotal: a few anonymous smokers described in a US patent document (US 5,026,697), plus testimonials on clinic marketing pages. Neither is peer-reviewed, controlled or systematically followed up.

Bottom line: evidence for ibogaine to quit smoking or vaping is limited to rodent experiments, receptor pharmacology and anecdotes. Whether it helps people stop using nicotine, for how long, and at what risk, is unknown.

Partly because of ibogaine's cardiac and psychoactive effects, researchers have studied related molecules.

Noribogaine. In a 2015 rat study, oral noribogaine reduced intravenous nicotine self-administration in a dose-dependent way, by up to 64% compared with saline. At the doses tested, the effect was similar to varenicline. It also reduced responding for palatable food pellets, by 23% at the highest dose, so the effect was not entirely specific to nicotine. The study was small, with 14 rats trained to self-administer nicotine, and included only males. No human trial of noribogaine for nicotine dependence has been published. In a small placebo-controlled human trial for another indication, noribogaine prolonged the QTc interval in proportion to dose.

18-methoxycoronaridine (18-MC). This synthetic ibogaine congener is designed to act more selectively at α3β4 nicotinic receptors. In rat studies it reduced nicotine-induced dopamine release and nicotine preference. A Phase 1 study of oral 18-MC in healthy volunteers is listed as completed on ClinicalTrials.gov. We found no published efficacy trial of 18-MC for nicotine dependence in humans.

So searches for noribogaine nicotine or 18-MC nicotine lead to research that is still at the preclinical or early safety stage. These compounds are not available as approved treatments.

Ibogaine is a Schedule I controlled substance in the United States and is not approved for any medical use there. People who pursue it usually travel to clinics in countries such as Mexico, where oversight varies widely. This page is educational information, not medical advice.

Protocols at clinics that follow published safety guidance typically include:

• Pre-treatment screening: a 12-lead ECG to measure the QTc interval, blood tests for electrolytes (especially potassium and magnesium) and liver function, a full medication review, and often an echocardiogram or cardiology assessment.
• Continuous cardiac monitoring during dosing and for an extended period afterward, because ibogaine and noribogaine effects on heart rhythm can last well beyond the acute experience.
• On-site resuscitation capability, including a defibrillator, staff trained in advanced cardiac life support, and a plan for transfer to a hospital.
• Psychological preparation and aftercare, since the experience can last many hours and can be intensely distressing.

People asking about ibogaine nicotine treatment Mexico cost should know that we have no verified data on pricing for nicotine-specific programs. Price is also a poor proxy for safety. Asking a clinic exactly how it screens, monitors and handles cardiac emergencies tells you more than its fee does.

People have died during or after ibogaine treatment, in clinics with medical staff present as well as outside them. A review of fatalities reported from 1990 through 2008 identified 19 deaths. In 12 of the 14 cases with adequate postmortem data, pre-existing medical conditions (mainly cardiovascular) or other substances explained or contributed to the death.

How ibogaine affects the heart:

• Ibogaine blocks hERG potassium channels, which can prolong the QT interval.
• Case reports describe torsade de pointes, ventricular tachycardia, bradycardia and asystole.
• The long-lasting metabolite noribogaine also prolongs QTc, so risk can continue after the acute effects fade.

Cardiac monitoring can catch a dangerous rhythm early enough to treat it. It does not prevent one, and it can miss one. A clinical setting lowers some risks but does not make ibogaine safe.

Considerations specific to nicotine users:

• Long-term smoking is a major cause of coronary artery disease, hypertension and other cardiovascular conditions, and these are the comorbidities most often implicated in ibogaine deaths. Some of those conditions may not yet have been diagnosed.
• Ibogaine is converted to noribogaine mainly by the liver enzyme CYP2D6. Bupropion, a common cessation medication, inhibits CYP2D6, and some antidepressants and other drugs do too. How ibogaine interacts with varenicline, bupropion or high-dose NRT has not been studied.
• Stopping nicotine can be weighed against risks that are far smaller. Unlike stopping some other substances, stopping nicotine is not medically dangerous in itself, so there is no medical urgency that would justify accepting a high-risk intervention.

Commonly cited contraindications include:

• structural heart disease, coronary disease or heart failure
• prolonged QTc at baseline, or a personal or family history of long-QT syndrome or unexplained sudden death
• low potassium or magnesium
• QT-prolonging medications
• significant liver disease
• a history of psychosis or bipolar disorder
• pregnancy

This list is not exhaustive. Only an individual medical evaluation can identify a particular person's risks.

The main unanswered questions about ibogaine for nicotine addiction are basic ones:

• Efficacy in humans: No controlled human data show whether ibogaine produces abstinence from smoking, vaping or pouches, at any dose.
• Durability: Rat studies suggest that effects on nicotine intake may be shorter-lived than effects seen with other drugs. Whether any human benefit would last weeks or years is unknown.
• Risk–benefit balance: Proven treatments already exist and come with well-characterized safety profiles. Any future trial would need to show that ibogaine adds benefit large enough to justify its cardiac risk.
• Product differences: It is unknown whether people dependent on vapes or pouches would respond any differently from smokers.
• Safer analogues: It remains to be seen whether compounds such as 18-MC can keep the anti-nicotine effects seen in animals while reducing cardiac and psychoactive effects. Human efficacy data have not been published.

Until those questions are studied in properly designed trials, the honest summary is this: interesting preclinical findings, no human efficacy evidence, and a documented risk of fatal cardiac events. Anyone trying to stop using nicotine can talk with a clinician or call a quitline about treatments with established track records.